Apnimed Secures Up to $150 Million in Debt Financing with HealthCare Royalty Partners to Support Planned AD109 Commercial Launch

Strengthens balance sheet to support commercial readiness and planned U.S. launch of AD109 oral pill for the treatment of Obstructive Sleep Apnea (OSA) On track to submit New Drug Application (NDA) for AD109 later this quarter CAMBRIDGE, Mass., April 6, 2026 /PRNewswire/ -- Apnimed, Inc.,...